William Blair upgraded NASDAQ:BDSX from Market Perform to Outperform, with a significant improvement in financial metrics.Biodesix reported a quarterly loss of $0.49 per share, beating the expected loss of $1.05, and achieved a revenue of $28.76 million, surpassing estimates by 14.11%.The company forecasts a revenue guidance for fiscal year 2026 between $106 to $112 million, indicating a 23% growth.Biodesix, Inc. (NASDAQ:BDSX) is a diagnostic solutions company that operates within the Zacks Medical Services ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $1.2 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +53.33%. A quarter ago, it was expected that this company would post a loss of $1.6 per share when it actually produced a loss of $1.16, delivering a surprise of +27.5%.Over the last four quarters, the company has surpasse ...

Biodesix (NasdaqGM:BDSX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsChris Brinzey - PartnerRobin Harper Cowie - CFOScott Hutton - CEOWilliam Ruby - Equity Research AssociateConference Call ParticipantsAndrew Brackmann - Equity Research AnalystJohn Wilkin - Equity Research Analyst of Diagnostics and Life Science ToolsKyle Mikson - Managing Director and Senior Research AnalystThomas Flaten - Senior Research AnalystOperatorStanding by. Welcome to the Biodesix 4th quarter 2025 earni ...

Biodesix (NasdaqGM:BDSX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsChris Brinzey - PartnerRobin Harper Cowie - CFOScott Hutton - CEOWilliam Ruby - Equity Research AssociateConference Call ParticipantsAndrew Brackmann - Equity Research AnalystJohn Wilkin - Equity Research Analyst of Diagnostics and Life Science ToolsKyle Mikson - Managing Director and Senior Research AnalystThomas Flaten - Senior Research AnalystOperatorStanding by. Welcome to the Biodesix fourth quarter 2025 ea ...

Biodesix (NasdaqGM:BDSX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker4Standing by. Welcome to the Biodesix 4th quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 agai ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39659 Biodesix, Inc. (Exact name of Registrant as specified in its Charter) Delaware 20-3986492 (State or other jurisdiction of incor ...

Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Exhibit 99.1 Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, CO, February 26, 2026 – Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and oper ...

Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fi ...

Core Viewpoint - Biodesix, Inc. will release its financial results for Q4 and the full year of 2025 on February 26, 2026, followed by a conference call to discuss these results and provide a business update [1]. Company Overview - Biodesix is a leading diagnostic solutions company focused on improving clinical care and outcomes for patients, particularly in lung disease [3]. - The company offers diagnostic tests such as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, which aid in clinical decision-making [3]. - Biodesix Development Services support biopharmaceutical and life sciences institutions in developing diagnostic tests and therapeutics [3].